FDA Post-Marketing Drug Risk Surveillance Requires More Funding, IG Says
Executive Summary
An HHS Office of the Inspector General audit report on FDA handling of adverse drug reaction reporting may support the agency's call for more resources to address post-marketing drug safety.
You may also be interested in...
Chronic Conditions Should Be Focus To Improve Health Quality - IoM Report
Enhanced coordination of care for patients with chronic conditions would improve quality of healthcare in the U.S., an Institute of Medicine report says.
Chronic Conditions Should Be Focus To Improve Health Quality - IoM Report
Enhanced coordination of care for patients with chronic conditions would improve quality of healthcare in the U.S., an Institute of Medicine report says.
Off Label Drug Use Data To Be Required In Periodic Safety Updates - FDA
Pharmaceutical companies will be asked to provide postmarketing drug usage information in their periodic safety update reports, including use in off label indications, under a proposed FDA rule due out later this year.